• To review evidence-based processes used in UK cancer funding decisions, using biologics in metastatic colorectal cancer (mCRC) as a case study.
• The English Cancer Drugs Fund (CDF) was introduced in 2010 to provide access to cancer drugs not routinely available on the National Health Service (NHS).
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• In its first year (2010/11), the Department of Health allocated £50million to the interim CDF. This has increased to £340million for 2015/16, and its future from April 2016 is uncertain.
• The criteria for CDF reimbursement relies on the cost and the degree of clinical benefit of a drug relative to other drug treatments using a scoring system based on the strength and quality of the evidence of clinical benefit (progression-free survival (PFS), overall survival (OS), quality of life (QOL), toxicity & unmet need).
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• CDF assessments focus on a comparative analysis using randomised controlled trial (RCT) data, rather than an assessment of potential survival gains the technology may afford in the real world.
• Early access and adoption of medical therapies via the CDF can contribute to achieving greater survival gains. For example, in mCRC, access to biologics has helped improve 5 year OS gains from 18.0 months pre-biologics (1998) (1999) (2000) to 29.2 months (2004) (2005) (2006) in the mid-2000s.
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• However, the current focus of the CDF scoring system on pre-launch RCTs may miss value gained from innovation-in-use, which would undervalue the survival gains achieved through real-world experience.
• Analysis of peer-reviewed literature reporting OS in mCRC in RCTs and in real world studies (RWSs).
• Investigation of use of RCTs and RWSs in UK CDF decisions, using Avastin ® [bevacizumab, Roche] and Erbitux ® [cetuximab, Merck] as examples.
• Pragmatic literature review of survival gains for both drugs in combination with several chemotherapy backbones in RWSs during the post biologics era.
• Recent RWSs report median OS levels in mCRC that are several months longer than those seen in prebiologic RCTs (approximately 29.1 months in the post-biologic era versus 17.4 months pre-biologics, an incremental survival benefit of 11.7 months). 4, 5 • The CDF decision summaries indicate that clinical innovation and pathway optimisation are not considered in reimbursement decision making (Tables 1 and 2 ). The evidence to support the decision to reimburse is limited as the focus for demonstrating value relies on RCT data.
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• Incremental improvements in OS can be driven by clinician experience with new technologies.
• In mCRC more than half of the real world gains in overall survival have been realised during the era in which clinicians have been able to treat with biologics and alternative chemotherapy backbones (Table 3 ).
• The Cancer Drugs Fund (CDF) facilitates earlier access and enables the UK National Health Service to realise the full scope of the benefits of innovative technologies, overcoming the deficiencies currently inherent in NICE and clinical reference group processes. Therefore, considerations for delisting of technologies from the CDF should be made in the light of data from RWSs as well as pre-launch data.
• A Commissioning-Through-Evaluation-type scheme could enable interim funding of new treatments enabling cancer drugs to be assessed by the CDF using core RCT data plus continuous assessment of real-world outcomes over time to capture the value of clinical and pathway innovation as evidenced in both Erbitux and Avastin examples. 
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